ICON Releases its 2021 ESG Report
06 Septembre 2022 - 10:15PM
Business Wire
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence
and clinical research organisation, today releases its 2021
Environmental, Social and Governance (ESG) Report.
The report outlines how ICON is delivering on its ESG
commitments and measured its performance in a number of key areas,
including the social impact it is having on advancing public
health, its continued diversity and inclusion focus, how it
conducts its business sustainably and its commitment to ethics and
quality.
On the publication of the report, Steve Cutler, CEO, ICON
commented: “This report showcases ICON’s commitment to delivering
positive impacts for our colleagues, our customers, our communities
and the patients we serve. I am proud of the progress we have made
on our ESG plans and priorities as shown by the report and I am
excited about the further progress we will make going forward.”
Examples of how ICON progressed its ESG commitments in 2021
include:
Advancing public health
ICON’s work spans continents, delivering services in developed
countries and traditionally underserved regions and helps to
improve access to healthcare for people worldwide.
ICON did significant work in 2021 in the fight against COVID-19.
This included providing clinical trials services to the Pfizer
(NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) investigational COVID-19
vaccine programme, which was the first COVID-19 vaccine to receive
FDA approval. Overall in 2021, ICON supported 26 drug
approvals.
In 2021, the company invested in patient centric innovation
using technology and partnerships. In addition to developing
strategic partnerships across the healthcare ecosystem to drive
increased access to healthcare, ICON has focused on innovative
approaches and technologies to drive progress in clinical
research.
Focus on diversity and inclusion
In 2021, ICON focused on promoting diversity within its own
company and the industry overall. From a patient perspective, one
of ICON’s key ambitions is to make it easier for patients, across
all dimensions of diversity, to be part of clinical research. In
its work with Pfizer and BioNTech, ICON supported their Phase 3,
late-stage study of the COVID-19 vaccine in enrolling over 40% of
participants from diverse backgrounds. In order to increase
diversity of participation in clinical trials, ICON has also
focused on clinical research as a care option (CRAACO) and has
actively worked with the Association of Clinical Research
Organisations (ACRO) to support the industry in achieving greater
diversity and equity.
Within its own company, community groups are one of the ways in
which ICON promotes diversity, inclusion and belonging, by bringing
together employees with common identities and related interests.
These groups are:
- NOW@ICON: The Networking Organisation for Women at ICON
- PRIDE: Supporting LGBTQ+ colleagues and allies
- DAWN: The Disability Awareness Network
- SPACE: Supporting Parents and Carers Everywhere
- EmbRACE: Supporting all race and ethnic backgrounds
Conducting business sustainably
ICON is actively managing its environmental impact across its
global business. Progress achieved in 2021 included:
- 40% of the way to reducing electricity consumption by 20% by
2030.
- Since 2018, Scope 3 business travel emissions have decreased by
60%.
- Consolidated 37 office locations to align with new working
styles and business needs. This includes office building closures
and modifications and a flexible working policy.
Supporting communities
In addition to the pivotal role ICON played in COVID-19 vaccine
development, the company also participated in the UNICEF Corporate
Vaccine Alliance in 2021, donating significant funds to support the
purchase of 38,000 vaccine doses - one on behalf of each ICON
employee.
ICON also continued with its employee-led charitable donation
program, which has supported over 90 charities since 2012. During
2021, ICON donated $200,000 split between 20 organisations chosen
by employees. The selected organisations focus on a range of
critical issues from relieving poverty and homelessness to
improving child welfare through education and enhancing the lives
of people living with a variety of diseases.
For further information about ICON’s ESG efforts in 2021, please
visit:www.iconplc.com/about/esg/
About ICON plc
ICON is the world’s leading clinical research organisation,
powered by healthcare intelligence. From molecule to medicine, we
advance clinical research providing outsourced development and
commercialisation services to pharmaceutical, biotechnology,
medical device and government and public health organisations. We
develop new innovations, drive emerging therapies forward and
improve patient lives. With headquarters in Dublin, Ireland, ICON
employed approximately 40,500 employees in 119 locations in 53
countries as at June 30, 2022. For further information about ICON,
visit: www.iconplc.com.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220906005335/en/
Claire Quinn Corporate Communications, ICON plc +353 87 4066091
claire.quinn@iconplc.com Kate Haven Vice President Investor
Relations, ICON plc +1-888-381-7923 IR@iconplc.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024